The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Brain Amyloid Imaging
Open accessAbstract
Imaging of brain β-amyloid plaques with (18)F-labeled tracers for PET will likely be available in clinical practice to assist the diagnosis of Alzheimer disease (AD). With the rapidly growing prevalence of AD as the population ages, and the increasing emphasis on early diagnosis and treatment, brain amyloid imaging is set to become a widely performed investigation. All physicians reading PET scans will need to know the complex relationship between amyloid and cognitive decline, how to best acquire and display images for detection of amyloid, and how to recognize the patterns of tracer binding in AD and other causes of dementia. This article will provide nuclear medicine physicians with the background knowledge required for understanding this emerging investigation, including its appropriate use, and prepare them for practical training in scan interpretation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“This phase has been termed mild cognitive impairment (MCI) (37,38), but advances in biomarkers for AD have recently led to proposals for more definitive diagnoses such as “prodromal AD” by the International Working Party for New Research Criteria for the Diagnosis of AD (39) or “MCI due to AD” by the National Institut…”
BackgroundMild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“Compelling genetic data support this Ab-centric theory (21,22).”
BackgroundSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Petersen, R. C., Stevens, J. C., Ganguli, M., Tangalos, E. G., Cummings, J. L., & DeKosky, S. T. (2001) · Neurology · doi:10.1212/wnl.56.9.1133 · Cited by 2,065
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · cited 1×
“This phase has been termed mild cognitive impairment (MCI) (37,38), but advances in biomarkers for AD have recently led to proposals for more definitive diagnoses such as “prodromal AD” by the International Working Party for New Research Criteria for the Diagnosis of AD (39) or “MCI due to AD” by the National Institut…”
BackgroundDoody, R. S., Stevens, J. C., Beck, C., Dubinsky, R. M., Kaye, J. A., Gwyther, L., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., et al. (2001) · Neurology · doi:10.1212/wnl.56.9.1154 · Cited by 1,720
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Knopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey–Bloom, J., Relkin, N., Small, G. W., Miller, B., & Stevens, J. C. (2001) · Neurology · doi:10.1212/wnl.56.9.1143 · Cited by 1,410
Amyloid, the presenilins and Alzheimer’s disease
Hardy, J. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)01030-2 · Cited by 1,370 · cited 1×
“Compelling genetic data support this Ab-centric theory (21,22).”
BackgroundNeuropathology of older persons without cognitive impairment from two community-based studies
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., & Wilson, R. S. (2006) · Neurology · doi:10.1212/01.wnl.0000219668.47116.e6 · Cited by 1,336
Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117
Imaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
Self-citationFrequent amyloid deposition without significant cognitive impairment among the elderly
Aizenstein, H. J., Nebes, R. D., Saxton, J. A., Price, J. C., Mathis, C. A., Tsopelas, N. D., Ziolko, S. K., James, J. A., Snitz, B. E., Houck, P. R., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.1509 · Cited by 1,059
[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986
Self-citationSilverman, D. H. S., Small, G. W., Chang, C. Y., Lu, C. S., de Aburto, M. A. K., Chen, W., Czernin, J., Rapoport, S. I., Pietrini, P., Alexander, G. E., et al. (2001) · JAMA · doi:10.1001/jama.286.17.2120 · Cited by 951
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933 · cited 1×
“The regional retention of 11C-PiB reflects the regional density of Ab plaques, as reported at autopsy (55,56) and as measured by quantification of immunohistochemical staining of brain slices, with a higher plaque density in the frontal cortex than in the hippocampus, consistent with previous neuropathologic and 11C-P…”
ResultFagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · cited 2×
“The pathologic biomarkers of AD are Ab imaging and cerebrospinal fluid assay of the amyloid peptide, Ab42.”
BackgroundLongitudinal assessment of Aβ and cognition in aging and Alzheimer disease
Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22248 · Cited by 833
Self-citationNeuropathology of Alzheimer's Disease
Perl, D. P. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20157 · Cited by 825
Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., Mathis, C. A., Klunk, W. E., Masters, C. L., & Rowe, C. C. (2007) · Brain · doi:10.1093/brain/awm238 · Cited by 789
Self-citationReiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900345106 · Cited by 785
PET imaging of amyloid deposition in patients with mild cognitive impairment
Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A., Ringheim, A., Långström, B., & Nordberg, A. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.03.029 · Cited by 728
Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B
Price, J. C., Klunk, W. E., Lopresti, B. J., Lu, X., Hoge, J. A., Ziolko, S. K., Holt, D. P., Meltzer, C. C., DeKosky, S. T., & Mathis, C. A. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600146 · Cited by 720
Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701
Wong, D. F., Rosenberg, P. B., Zhou, Y., Kumar, A., Raymont, V., Ravert, H. T., Dannals, R. F., Nandi, A., Brašić, J. R., Ye, W., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.069088 · Cited by 684 · cited 2×
“These are florbetaben (4,8,9), florbetapir (5,6), and flutemetamol (7).”
BackgroundRowe, C. C., Ackerman, U., Browne, W., Mulligan, R., Pike, K. L., O'Keefe, G., Tochon-Danguy, H., Chan, G., Berlangieri, S. U., Jones, G., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70001-2 · Cited by 671
Self-citationUse of structural magnetic resonance imaging to predict who will get Alzheimer's disease
Killiany, R. J., Gomez-Isla, T., Moss, M., Kikinis, R., Sandor, T., Jolesz, F., Tanzi, R., Jones, K., Hyman, B. T., & Albert, M. S. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200004)47:4<430::aid-ana5>3.0.co;2-i · Cited by 664
18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial
Vandenberghe, R., Van Laere, K., Ivanoiu, A., Salmon, E., Bastin, C., Triau, E., Hasselbalch, S., Law, I., Andersen, A., Korner, A., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22068 · Cited by 646
Barthel, H., Gertz, H.-J., Dresel, S., Peters, O., Bartenstein, P., Buerger, K., Hiemeyer, F., Wittemer-Rump, S. M., Seibyl, J., Reininger, C., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70077-1 · Cited by 591
Conversion of amyloid positive and negative MCI to AD over 3 years: An 11 C-PIB PET study
Okello, A., Koivunen, J., Edison, P., Archer, H. A., Turkheimer, F. E., Någren, K., Bullock, R., Walker, Z., Kennedy, A., Fox, N. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b23564 · Cited by 527
Imaging of amyloid burden and distribution in cerebral amyloid angiopathy
Johnson, K. A., Gregas, M., Becker, J. A., Kinnecom, C., Salat, D. H., Moran, E. K., Smith, E. E., Rosand, J., Rentz, D. M., Klunk, W. E., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21164 · Cited by 495
New Frontiers in Alzheimer's Disease Genetics
Tanzi, R. E., & Bertram, L. (2001) · Neuron · doi:10.1016/s0896-6273(01)00476-7 · Cited by 463
11 C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration
Rabinovici, G. D., Furst, A. J., O'Neil, J. P., Racine, C. A., Mormino, E. C., Baker, S. L., Chetty, S., Patel, P., Pagliaro, T. A., Klunk, W. E., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000259035.98480.ed · Cited by 410
Mathis, C. A., Bacskai, B. J., Kajdasz, S. T., McLellan, M. E., Frosch, M. P., Hyman, B. T., Holt, D. P., Wang, Y., Huang, G.-F., Debnath, M. L., et al. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00734-x · Cited by 403
Neuropathologic Outcome of Mild Cognitive Impairment Following Progression to Clinical Dementia
Jicha, G. A., Parisi, J. E., Dickson, D. W., Johnson, K., Cha, R., Ivnik, R. J., Tangalos, E. G., Boeve, B. F., Knopman, D. S., Braak, H., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.674 · Cited by 399
Mild cognitive impairment: transition between aging and Alzheimer's disease.
Petersen, R. C. (2000) · PubMed · Cited by 395
Klunk, W. E., Price, J. C., Mathis, C. A., Tsopelas, N. D., Lopresti, B. J., Ziolko, S. K., Bi, W., Hoge, J. A., Cohen, A. D., Ikonomovic, M. D., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0730-07.2007 · Cited by 389
Amyloid Imaging with18F-Florbetaben in Alzheimer Disease and Other Dementias
Villemagne, V. L., Ong, K., Mulligan, R. S., Holl, G., Pejoska, S., Jones, G., O'Keefe, G., Ackerman, U., Tochon-Danguy, H., Chan, J. G., et al. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.089730 · Cited by 372
Self-citationUsefulness of MRI measures of entorhinal cortex versus hippocampus in AD
de Leon, M., Bobinski, M., Convit, A., Wolf, O., & Insausti, R. (2001) · Neurology · doi:10.1212/wnl.56.6.820 · Cited by 348
Molecular Imaging With Pittsburgh Compound B Confirmed at Autopsy: A Case Report
Bacskai, B. J., Frosch, M. P., Freeman, S. H., Raymond, S. B., Augustinack, J. C., Johnson, K. A., Irizarry, M. C., Klunk, W. E., Mathis, C. A., DeKosky, S. T., et al. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.431 · Cited by 341
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics
Shaw, L. M., Korecka, M., Clark, C. M., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2176 · Cited by 339
Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD
Xu, Y., Jack, C. R., O’Brien, P. C., Kokmen, E., Smith, G. E., Ivnik, R. J., Boeve, B. F., Tangalos, R. G., & Petersen, R. C. (2000) · Neurology · doi:10.1212/wnl.54.9.1760 · Cited by 336
Klunk, W. E., Wang, Y., Huang, G.-F., Debnath, M. L., Holt, D. P., Shao, L., Hamilton, R. L., Ikonomovic, M. D., DeKosky, S. T., & Mathis, C. A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-06-02086.2003 · Cited by 309
PET amyloid ligand [ 11 C]PIB uptake is increased in mild cognitive impairment
Kemppainen, N. M., Aalto, S., Wilson, I. A., Någren, K., Helin, S., Brück, A., Oikonen, V., Kailajärvi, M., Scheinin, M., Viitanen, M., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000260969.94695.56 · Cited by 308
Villemagne, V. L., Pike, K. E., Darby, D., Maruff, P., Savage, G., Ng, S., Ackermann, U., Cowie, T. F., Currie, J., Chan, S. G., et al. (2008) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2008.02.008 · Cited by 292
Self-citationNg, S., Villemagne, V. L., Berlangieri, S., Lee, S.-T., Cherk, M., Gong, S. J., Ackermann, U., Saunder, T., Tochon-Danguy, H., Jones, G., et al. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.037762 · Cited by 258
Self-citationMolecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics
Masters, C. L., Cappai, R., Barnham, K. J., & Villemagne, V. L. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03989.x · Cited by 241
Self-citationNeuropathology of Alzheimer’s disease: a critical update
Jellinger, K. A., & Bancher, C. (1998) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-7508-8_8 · Cited by 231
Staging of Alzheimer-Related Cortical Destruction
Braak, H., & Braak, E. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004973 · Cited by 217
In vivo amyloid imaging with PET in frontotemporal dementia
Engler, H., Santillo, A. F., Wang, S. X., Lindau, M., Savitcheva, I., Nordberg, A., Lannfelt, L., Långström, B., & Kilander, L. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0523-1 · Cited by 214
Lockhart, A., Ye, L., Judd, D. B., Merritt, A. T., Lowe, P. N., Morgenstern, J. L., Hong, G., Gee, A. D., & Brown, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412056200 · Cited by 213
Mild Cognitive Impairment: Current Research and Clinical Implications
Petersen, R. (2007) · Seminars in Neurology · doi:10.1055/s-2006-956752 · Cited by 208
Cairns, N. J., Ikonomovic, M. D., Benzinger, T., Storandt, M., Fagan, A. M., Shah, A. R., Reinwald, L. T., Carter, D., Felton, A., Holtzman, D. M., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.279 · Cited by 205
Drzezga, A., Grimmer, T., Henriksen, G., Stangier, I., Perneczky, R., Diehl-Schmid, J., Mathis, C. A., Klunk, W. E., Price, J., & DeKosky, S. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2007.09.020 · Cited by 204
Leinonen, V. (2008) · Archives of Neurology · doi:10.1001/archneur.65.10.noc80013 · Cited by 199 · cited 1×
“The regional retention of 11C-PiB reflects the regional density of Ab plaques, as reported at autopsy (55,56) and as measured by quantification of immunohistochemical staining of brain slices, with a higher plaque density in the frontal cortex than in the hippocampus, consistent with previous neuropathologic and 11C-P…”
ResultVillemagne, V. L., Ataka, S., Mizuno, T., Brooks, W. S., Wada, Y., Kondo, M., Jones, G., Watanabe, Y., Mulligan, R., Nakagawa, M., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.285 · Cited by 174
Self-citationMasters, C. L., & Beyreuther, K. (2006) · Brain · doi:10.1093/brain/awl251 · Cited by 160
11 C-PIB binding is increased in patients with cerebral amyloid angiopathy–related hemorrhage
Ly, J. V., Donnan, G. A., Villemagne, V. L., Zavala, J. A., Ma, H., O'Keefe, G., Gong, S. J., Gunawan, R. M., Saunder, T., Ackerman, U., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cef7e3 · Cited by 157
Self-citationContribution of Structural Neuroimaging to the Early Diagnosis of Alzheimer’s Disease
de Leon, M. J., Convit, A. J., DeSanti, S., Carroll, R., GEORGE, A. E., Rusinek, H., Bobinski, M., Wísniewski, H. M., & Louis, L. A. S. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004900 · Cited by 143
Koivunen, J., Verkkoniemi, A., Aalto, S., Paetau, A. E., Ahonen, J.-P., Viitanen, M. H., Någren, K., Rokka, J., Haaparanta‐Solin, M., Kalimo, H., et al. (2008) · Brain · doi:10.1093/brain/awn107 · Cited by 116
1997 IPA/Bayer Research Awards in Psychogeriatrics
Simpson, S. W., Baldwin, R. C., Jackson, A., & Burns, A. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004432 · Cited by 115
Amyloid imaging in Alzheimer??s disease
Nordberg, A. K. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3281a47744 · Cited by 107
Biomarkers for Early Detection of Alzheimer Pathology
Clark, C. M., Davatzikos, C. A., Borthakur, A., Newberg, A. B., Leight, S., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Neurosignals · doi:10.1159/000109754 · Cited by 105
Delineation of Positron Emission Tomography Imaging Agent Binding Sites on β-Amyloid Peptide Fibrils
Ye, L., Morgenstern, J. L., Gee, A. D., Hong, G., Brown, J., & Lockhart, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501285200 · Cited by 97
Efficacy and Safety of OK-432 Sclerotherapy for Giant Cystic Hygroma in a Newborn
Samuel, M., McCarthy, L., & Boddy, S. A. (2000) · Fetal Diagnosis and Therapy · doi:10.1159/000020983 · Cited by 96
The Epidemic of Alzheimer??s Disease
Johnson, N., Davis, T., & Bosanquet, N. (2000) · PharmacoEconomics · doi:10.2165/00019053-200018030-00002 · Cited by 79
Price (1999) · doi:10.1002/1531-8249(199903)45:3
(1999) · doi:10.1002/1531-8249(199912)46:6<860::aid-ana8>3.0.co;2-m
Cited by
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Self-citationThe Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
Self-citation18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease
Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Tago, T., Hiraoka, K., Watanuki, S., Shidahara, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.164848 · Cited by 330
“When compared with reported tau radiotracers such as 11C-PBB3 and 18F-T807, a drawback of 18F-THK5117 is high white-matter retention, which is frequently observed with 18F-labeled amyloid radiotracers (33).”
Resultvan Oostveen, W. M., & de Lange, E. C. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042110 · Cited by 297
PET/MRI for Neurologic Applications
Catana, C., Drzezga, A., Heiss, W.-D., & Rosen, B. R. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.105346 · Cited by 288
Metadata
- Authors
- Rowe, C. C., & Villemagne, V. L.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2011-09-14
- Volume
- 52
- Issue
- 11
- Pages
- 1733-1740
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W1916193671
- Cited by
- 261
- References
- 79
- FWCI
- 13.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.